Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy, Multiple Sclerosis Journal, vol.79, issue.4 ,
DOI : 10.1016/j.jpba.2011.01.006
Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo, Nature Biotechnology, vol.179, issue.8, pp.767-71, 2009. ,
DOI : 10.4049/jimmunol.179.5.3325
Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody, Analytical Biochemistry, vol.411, issue.2, pp.271-277, 2011. ,
DOI : 10.1016/j.ab.2011.01.001
Development and validation of immunoassays to quantify the half-antibody exchange of an IgG4 antibody, natalizumab (Tysabri??) with endogenous IgG4, Journal of Pharmaceutical and Biomedical Analysis, vol.55, issue.1, pp.168-75, 2011. ,
DOI : 10.1016/j.jpba.2011.01.006
Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis, Multiple Sclerosis Journal, vol.19, issue.5, pp.593-600, 2013. ,
DOI : 10.1136/ard.2006.057406
New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies, Journal of Neuroinflammation, vol.277, issue.Pt 8, p.164, 2016. ,
DOI : 10.1016/j.jneuroim.2014.10.011
A Randomized Trial Evaluating Various Administration Routes of Natalizumab in Multiple Sclerosis, The Journal of Clinical Pharmacology, vol.8, issue.1, 2016. ,
DOI : 10.1371/journal.pone.0053297
CD49d expression as a promising biomarker to monitor natalizumab efficacy, Journal of the Neurological Sciences, vol.314, issue.1-2, pp.138-180, 2012. ,
DOI : 10.1016/j.jns.2011.10.005
Natalizumab treatment reduces endothelial activity in MS patients, Journal of Neuroimmunology, vol.227, issue.1-2, pp.190-194, 2010. ,
DOI : 10.1016/j.jneuroim.2010.07.012
The incidence and significance of antinatalizumab antibodies: results from AFFIRM and SENTINEL, Neurology, 2007. ,